A pilot trial evaluating co-infusion of mesothelin- and CD19-targeted CAR-T cells reported feasibility and disease stabilization in 1 of 3 metastatic PC patients (Ko et al. 2020). This evidence concerns the gene CD19 and pachyonychia congenita.